NDC 70242-121 - SUEROLYTE Oral Electrolyte Solution Pineapple Flavor
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70242-121
- Package NDCs from labels
- 70242-121-33
- Manufacturer
- Dannso Corp./d.b.a. Essential Products | Alfa Vitamins Laboratories Inc
- Effective date
- 2015-08-14
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| SUEROLYTE Oral Electrolyte Solution Pineapple Flavor | Dannso Corp./d.b.a. Essential Products | Alfa Vitamins Laboratories Inc | 2015-08-14 | DIETARY SUPPLEMENT |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70242-121-33 | SUEROLYTE Oral Electrolyte Solution Pineapple Flavor | 1 L in 1 BOTTLE | LIQUID | 1 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 70242-121 | SUEROLYTE ORAL ELECTROLYTE SOLUTION PINEAPPLE FLAVOR ( DEXTROSE, CITRIC ACID, POTASSIUM CITRATE, SODIUM CHLORIDE,SODIUM CITRATE, SUCRALOSE, ACESULFAME POTASSIUM, ZINC GLUCONATE, POTASSIUM SORBATE) LIQUID [DANNSO CORP./D.B.A. ESSENTIAL PRODUCTS] | 1 | 1 package rows | 20160530_abaae728-8c07-4b00-8abe-71aa1a4ef514.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | ee831456-5962-4d5e-ad0c-69ab85860453 | 2020-06-03 | LX22YL083G | |
| 0.9% SODIUM CHLORIDE | 0.9% SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | a62b71db-8ba2-6f6b-e053-2a95a90a29d1 | 2020-05-21 | Warnings, Adverse reactions | 451W47IQ8X |
| LACTATED RINGERS AND DEXTROSE | SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE, AND DEXTROSE MONOHYDRATE | HF Acquisition Co LLC, DBA HealthFirst | a62cf623-9b8a-37e0-e053-2995a90add5b | 2020-05-21 | Warnings, Adverse reactions | 451W47IQ8X LX22YL083G |
| Hay Fever | APIS MELLIFICA, ECHINACEA, HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACONITUM NAPELLUS, ALFALFA, ALLIUM CEPA, AMBROSIA ARTEMISIAEFOLIA, AMMONIUM CARBONICUM, ARALIA RACEMOSA, ARSENICUM ALBUM, ARTEMISIA VULGARIS, ARUNDO MAURITANICA, BELLIS PERENNIS, BERBERIS VULGARIS, BRYONIA, CALLUNA VULGARIS, FLOS, CHELIDONIUM MAJUS, CHENOPODIUM ANTHELMINTICUM, CISTUS CANADENSIS, DROSERA, DULCAMARA, EUPATORIUM PERFOLIATUM, EUPHRASIA OFFICINALIS, FAGUS SYLVATICA, FRAXINUS AMERICANA, GELSEMIUM SEMPERVIRENS | Newton Laboratories, Inc. | a6045b91-d361-2731-e053-2a95a90a9772 | 2020-05-18 | Warnings | 451W47IQ8X |
| Isolyte S | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE, AND MAGNESIUM CHLORIDE | B. Braun Medical Inc. | 7e8fe27f-ff82-48c1-9bf6-3c589c8e985d | 2020-05-14 | Warnings, Adverse reactions | 451W47IQ8X |
| V Doctor pure chlorine dioxide | SODIUM CHLORITE | Pure O2 | a492a03c-c28e-fcd6-e053-2a95a90a65d4 | 2020-05-01 | Warnings | G538EBV4VF |
| DEXTROSE AND SODIUM CHLORIDE | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE | Fresenius Kabi USA, LLC | b825c9c4-f2fb-4a4a-9d8c-fb020ad07e93 | 2020-04-30 | Warnings, Adverse reactions | 451W47IQ8X LX22YL083G |
| 0.9% SODIUM CHLORIDE | 0.9% SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | a2b8220f-e33a-51c3-e053-2995a90a0734 | 2020-04-07 | Warnings, Adverse reactions | 451W47IQ8X |
| 0.9% SODIUM CHLORIDE | 0.9% SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | a2bba76a-08ce-6902-e053-2995a90ab9c9 | 2020-04-07 | Warnings, Adverse reactions | 451W47IQ8X |
| Dextrose | DEXTROSE MONOHYDRATE | Baxter Healthcare Company | 7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e | 2020-02-27 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose and Electrolyte No. 48 | SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, MONOBASIC POTASSIUM PHOSPHATE, SODIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | b283a454-0c20-4fbf-92d3-dae1f3cd3cad | 2020-02-13 | Warnings, Adverse reactions | 451W47IQ8X LX22YL083G |
| Sodium Chloride | SODIUM CHLORIDE | Baxter Healthcare Corporation | fbc01464-8885-4075-af41-911ffec5ae92 | 2020-01-27 | Warnings, Adverse reactions | 451W47IQ8X |
| Sterile Water | WATER | Baxter Healthcare Company | 8bcf5572-49e1-4302-9522-56f57904cb4a | 2019-12-29 | Warnings, Adverse reactions | 059QF0KO0R |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 14445dfd-6041-40cd-a043-3f4da6bcb9c1 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 2557199a-5f60-49d8-b093-1e0700211243 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 794f724c-87f0-49c1-9b26-c9e491978313 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 5c7d3287-883a-459b-9214-074a583c8a59 | 2019-11-18 | LX22YL083G | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 448a1dc5-7a98-4b2f-82af-4b92de05cfc3 | 2019-11-18 | LX22YL083G | |
| Plasma-Lyte A | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE AND MAGNESIUM CHLORIDE | Baxter Healthcare Corporation | 6ec9e61c-2c26-402f-8604-f446b2e34058 | 2019-08-05 | Warnings, Adverse reactions | 451W47IQ8X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.